The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. Tesaro has filed a lawsuit ...

LONDON, Oct 29 (Reuters) - GSK (GSK.L), opens new tab raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico ...

GSK has successfully appealed a ruling by the U.K. marketing watchdog that determined a trio of its COVID-19 vaccine press releases had brought discredit on the pharma industry. The case is the latest ...

July 28 (Reuters) - Britain's GSK (GSK.L), opens new tab and China's Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab have agreed on a $500 million deal to develop up to a dozen new ...

NEW YORK – Concentra Biosciences continued its shopping spree of struggling biotechs this week, entering into an agreement to buy immuno-oncology company iTeos Therapeutics. On Monday, iTeos announced ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities is only natural. But that redistribution of resources will mean job cuts ...

The latest health news roundup covers GSK and Spero halting a UTI drug trial after achieving study goals, Alcon's FDA-approved dry-eye drug, CVS’ legal challenge against an Arkansas law, Granules ...

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the market ...